

**Current Status of the Implication of the
Clinical Practice Pattern in Hemodialysis
Prescription in Regular Hemodialysis
Patients in Egypt (Assuit sector B)**

Thesis submitted for partial fulfilment of Master degree in Internal

By

Abd EL Razek Abd Elhamid Ali Mousa

M.B., B.Ch. (2002),

Faculty of Medicine, Ain Shams University

Supervised by

Prof. Dr. Magdy Mohammed Saed El sharawy

Professor of Internal Medicine and Nephrology,
Faculty of Medicine, Ain Shams University

Dr. Haitham Ezzat Abd El Aziz

Lecturer of Internal Medicine and Nephrology,
Faculty of Medicine, Ain-Shams University

Faculty of Medicine

Ain Shams University

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبَّحَانَكَ لَا أَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



*First, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really, I can hardly find the words to express my gratitude to **Prof. Dr. Magdy Mohammed Saed El sharawy** Professor of internal medicine and nephrology, faculty of medicine, Ain Shams University, for her supervision, continuous help, encouragement throughout this work and tremendous effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.*

*I would like also to express my sincere appreciation and gratitude to **Dr. Haitham Ezzat Abd El Aziz** lecturer of internal medicine and nephrology, faculty of medicine, Ain Shams University, for his continuous directions and support throughout the whole work,*

Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward, this work would not have ever been completed.



Abd EL Razek Abd Elhamid Ali

List of contents

<i>Title</i>	<i>Content</i>	<i>Pages</i>
1	List of abbreviations	ii
2	List of Tables	Vi
3	List of Figures	Vii
4	Introduction	1
5	Aim of the work	4
6	<u>Review of Literature</u> • Hemodialysis prescription • Guidelines for kidney disease • Anemia on chronic kidney disease • Renal osteodystrophy • Hemodialysis associated co-morbidities • Hemodialysis in EGYPT	5 28 44 51 58 64
7	Subjects and Methods	68
8	Results	72
9	Discussion	104
10	Summary and conclusion	114
11	References	119
12	Arabic summary	--

List of abbreviations

<i>ABD</i>	<i>Adynamic Bone Disease</i>
<i>ADPKD</i>	<i>Autosomal Dominant Polycystic Kidney Disease</i>
<i>AGE</i>	<i>Advanced Glycation Endproducts</i>
<i>AJKD</i>	<i>American Journal of Kidney Diseases</i>
<i>ANZSN</i>	<i>Australian and New Zealand Society of Nephrology</i>
<i>AV fistula</i>	<i>Arterio Venous Fistula</i>
<i>bAP</i>	<i>Bone Alkaline Phosphatase</i>
<i>BNP</i>	<i>B-type Natriuretic Peptides</i>
<i>BP</i>	<i>Blood Pressure</i>
<i>BUN</i>	<i>Blood Urea Nitrogen</i>
<i>CAPN</i>	<i>Canadian Association of Pediatric Nephrologists</i>
<i>CARI</i>	<i>Caring for Australian with Renal Impairment</i>
<i>CDC</i>	<i>Centers for Disease Control and prevention</i>
<i>CHF</i>	<i>Congestive Heart Failure</i>
<i>CHOIR</i>	<i>Correction of Hemoglobin and Outcomes In Renal Insufficiency</i>
<i>CHr</i>	<i>Reticulocyte Hb content</i>
<i>CKD 5D</i>	<i>Chronic kidney disease stage 5 on dialysis</i>
<i>CKD</i>	<i>Chronic kidney diseases</i>
<i>CKD-MBD</i>	<i>Chronic Kidney Disease-Mineral and Bone Disorder</i>
<i>CMB</i>	<i>Calcium Mass Balance</i>
<i>CPG</i>	<i>Clinical Practice Guidelines</i>
<i>CREATE</i>	<i>Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta</i>
<i>CSN</i>	<i>Canadian Society of Nephrology</i>
<i>cTns</i>	<i>Cardiac Troponins</i>
<i>CUA</i>	<i>Calcific Uremic Arteriolopathy</i>
<i>CVD</i>	<i>Cardiovascular Disease</i>
<i>DOPPS</i>	<i>Dialysis Outcomes and Practice Patterns Study</i>
<i>EBCT</i>	<i>Electron-Beam Computed Tomography</i>

List of abbreviations (cont.)

<i>EBPG</i>	<i>European Best Practice Guidelines</i>
<i>eKt/V</i>	<i>The Equilibrated Kt/V</i>
<i>EPO</i>	<i>Erythropoietin</i>
<i>ERA-EDTA</i>	<i>European Renal Association - European Dialysis and Transplant Association</i>
<i>ERBP</i>	<i>European Renal Best Practice</i>
<i>ERT</i>	<i>Evidence Review Team</i>
<i>ESA</i>	<i>Erythropoietin Stimulating Agent</i>
<i>ESRD</i>	<i>End Stage Renal Disease</i>
<i>FBC</i>	<i>Full Blood Count</i>
<i>FDA</i>	<i>US Food and Drug Administration</i>
<i>FGF</i>	<i>Fibroblast Growth Factor</i>
<i>GFR</i>	<i>Glomerular Filtration Rate</i>
<i>GN</i>	<i>Glomerulo Nephritis</i>
<i>GRADE</i>	<i>Grades of Recommendation, Assessment, Development, and Evaluation</i>
<i>Hb</i>	<i>Hemoglobin</i>
<i>HBV</i>	<i>Hepatitis-B Virus</i>
<i>HCV</i>	<i>Hepatitis C Virus</i>
<i>HD</i>	<i>Hemodialysis</i>
<i>HDF</i>	<i>Hemodiafiltration</i>
<i>HDP</i>	<i>Hemodialysis Product</i>
<i>HEMO study</i>	<i>The Hemodialysis Study</i>
<i>HIV</i>	<i>Human Immunodeficiency Virus</i>
<i>IL-1</i>	<i>Interleukin-1</i>
<i>Ipth</i>	<i>Intact Parathyroid Hormone</i>
<i>K/DOQI</i>	<i>National Kidney Foundation Kidney Disease Outcome Quality Initiative</i>
<i>KDIGO</i>	<i>Kidney Disease Global Outcomes Improvement initiative</i>

List of abbreviations (cont.)

<i>KHA</i>	<i>Board of Kidney Health Australia</i>
<i>KrU</i>	<i>Residual Renal Urea Clearance</i>
<i>LVH</i>	<i>Left Ventricular Hypertrophy</i>
<i>MICS</i>	<i>Malnutrition-inflammation complex syndrome</i>
<i>MOH</i>	<i>Egyptian Ministry of Health</i>
<i>nPCR</i>	<i>Normalized Protein Catabolic Rate</i>
<i>NT-proBNP</i>	<i>N-terminal prohormone of Brain Natriuretic Peptide</i>
<i>PAD</i>	<i>Peripheral Arterial Disease</i>
<i>PCI</i>	<i>Percutaneous Coronary Intervention</i>
<i>PEM</i>	<i>Protein energy malnutrition</i>
<i>PRCA</i>	<i>Pure Red Cell Aplasia</i>
<i>RA</i>	<i>Renal Association</i>
<i>RCTs</i>	<i>Randomised Controlled Trials</i>
<i>RKF</i>	<i>Residual kidney function</i>
<i>ROD</i>	<i>Renal Osteodystrophy</i>
<i>SCD</i>	<i>Sudden Cardiac Death</i>
<i>SHPT</i>	<i>Secondary Hyperparathyroidism</i>
<i>SLE</i>	<i>Systemic Lupus Erythematosus</i>
<i>spKt/V</i>	<i>Single-pool Kt/V</i>
<i>SRI</i>	<i>The Solute Removal Index</i>
<i>stdKt/V</i>	<i>standard Kt/V</i>
<i>t-PA</i>	<i>Tissue Plasminogen Pctivator</i>
<i>TREAT</i>	<i>Trial to Reduce Cardiovascular Events with Aranesp® Therapy</i>
<i>TSAT</i>	<i>Transferrin Saturation</i>
<i>URR</i>	<i>Urea Reduction Ratio</i>
<i>USRDS</i>	<i>United States Renal Data System</i>
<i>VC</i>	<i>Vascular Calcification</i>
<i>VDR</i>	<i>Vitamin D Receptor</i>
<i>VDRA</i>	<i>Vitamin D Receptor Activators</i>
<i>WGs</i>	<i>Work Groups</i>
<i>β2m</i>	<i>Beta 2-microglobulin</i>

List of tables

Table	Title	Page
1	hemodialysis units in (Assuit sector B)governaerte	73
2	Gender distribution in the study population	74
3	Different causes of ESRD in the study population	75
4	Different co-morbidities in the study population	76
5	Work status in the study population	77
6	Dependency status in the study population	78
7	Wheel chair in the study population	79
8	Frequency of HD session/week in the study population	80
9	Age ,Duration of HD session, period of dialysis, dry weight and average weight gain in the study population	81
10	Sponsoring status in the study population	82
11	Type of vascular access in the study population	83
12	Frequency of access failure in the study population	84
13	The levels of Haemoglobin in the last 6 month in the study population .	85

14	History of blood transfusion in the study population	86
15	Type of ESA used by the study population	87
16	History of iron injection in the study population	88
17	History of adjuvant therapy in the study population (Vitamin B complex supplement)	89
18	<i>History of adjuvant therapy in the study population .(Folic acid supplement) .</i>	90
19	<i>History of adjuvant therapy in the study population .(L-Carnitine supplement)</i>	91
20	<i>History of adjuvant therapy in the study population (Vitamin D supplement) .</i>	92
21	The levels of Calcium, during 6 months covered by the study	93
22	phosphorus levels in the study population	94
23	Types of complications during HD session in the study population	95

24	Viral status in the study population(HCV).	96
25	Criteria of dialyzer used in the study population.	98
26	Criteria of dialysate used in the study population	99
27	Anticoagulants dose in the study population.	100

List of figures (cont.)

<i>Figure</i>	<i>Title</i>	<i>Page</i>
1	hemodialysis units in (Assuit sector B)governaerte	73
2	Gender distribution in the study population	74
3	Different co-morbidities in the study population	76
4	Work status in the study population	77
5	Dependency status in the study population	78

6	Wheel chair in the study population	79
7	Frequency of HD session/week in the study population	80
8	Sponsoring status in the study population	82
9	Type of vascular access in the study population	83
10	Frequency of access failure in the study population	84
11	The levels of Haemoglobin in the last 6 month in the study population .	85
12	History of blood transfusion in the study population	86

13	Type of ESA used by the study population	87
14	History of iron injection in the study population	88
15	History of adjuvant therapy in the study population (Vitamin B complex supplement)	89
16	<i>History of adjuvant therapy in the study population .(Folic acid supplement) .</i>	90
17	<i>History of adjuvant therapy in the study population .(L-Carnitine supplement)</i>	91
18	<i>History of adjuvant therapy in the study population (Vitamin D supplement) .</i>	92
19	The levels of Calcium, during 6 months covered by the study	93
20	phosphorus levels in the study population	94
21	Types of complications during HD session in the study population	95
22	Viral status in the study population(HCV).	96
23	Criteria of dialyzer used in the study population	99
24	Anticoagulants dose in the study population	100



Introduction

